Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1180967

	registered interest
	date	26/02/2020
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Vaccination: Research
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Department for Business Energy and Industrial Strategy, if he will make an assessment of the potential merits of directing UKRI to fund research into platform vaccine and diagnostic tools to support the development of vaccines during a potential pandemic.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	21237
	answer	answer is ministerial correction date of answer 03/03/2020 answer text <p>We work with the Department of Health and Social Care (DHSC), Department for International Development, and UK Research and Innovation (UKRI) to support research on platform vaccine technologies and diagnostic tools that can be utilised as a rapid response during a pandemic. These form a component of the current DHSC and UKRI COVID-19 rapid-response call for proposals to address the threat of this novel coronavirus. Platform vaccines and diagnostics are an integral part of UKRI’s current approach for the development and translation of research findings into tangible benefits, with research funded across UKRI councils</p><p> </p><p>DHSC and UKRI lead the UK Vaccine Network which brings together funders, industry and academia to identify and target investment opportunities for the most promising vaccines and vaccine technologies, including platform vaccine and diagnostic tools to combat infectious diseases with epidemic potential and to address structural issues related to the UK’s vaccine infrastructure.</p><p> </p><p>Through the Network two vaccine manufacturing hubs have been established to streamline vaccine manufacturing. A £10 million award to Professor Robin Shuttock at Imperial College London aims to revolutionise the vaccine manufacture, stabilisation and storage, reducing costs, increasing efficiency and improving prevention of existing and new diseases. A £7 million award to Professor Tarit Mukhopadhyay at University College London aims to establish the UK as a global centre for vaccine discovery, development and manufacture, while also ensuring that new vaccine manufacturing processes can be used in low and middle income countries.</p> answering member constituency Derby North answering member printed Amanda Solloway question first answered 03/03/2020 16:02:27 answering member 4372 label Biography information for Amanda Solloway
	tabling member	3960 label Biography information for Henry Smith

1285630

	registered interest
	date	10/02/2021
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Coronavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what plans his Department has to (a) conduct and (b) provide funding for external organisations to conduct research into the effectiveness of covid-19 vaccinations for (a) people with blood cancer and (b) other immunocompromised people.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	152472
	answer	answer is ministerial correction date of answer 26/02/2021 answer text <p>UKRI is currently funding one study of direct relevance to these areas. UKRI has allocated an initial £1.8 million to the OCTAVE study, led by Professor Iain McInnes, University of Glasgow, for a twelve-month period, and is considering a case for additional funding beyond this. OCTAVE is supporting research on vaccine responses in groups of immune-supressed individuals, including those with inflammatory disorders, high risk cancer patient groups, and patients with severe kidney and liver disease. Cancer patient groups include chronic lymphocytic leukaemia, myeloma, acute leukaemia, and bone marrow transplants. As the OCTAVE study is being managed as a single project it is not possible to give costs for the individual groups.</p><p> </p><p>In addition, there are proposals on vaccine responses in high-risk clinical groups under consideration as part of the UKRI COVID-19 Agile call, with announcements to be made shortly. Furthermore, UKRI continues to accept applications for COVID-19 related research, including on this topic, through its active calls, which can be found on the UKRI website.</p> answering member constituency Derby North answering member printed Amanda Solloway question first answered 26/02/2021 12:13:53 answering member 4372 label Biography information for Amanda Solloway
	tabling member	3960 label Biography information for Henry Smith